Activites

• 2006/12/27 Final act published in Official Journal
  • Regulation 2006/1920
  • OJ L 376 27.12.2006, p. 0001-0013
• 2006/12/12 Final act signed
• 2006/12/12 End of procedure in Parliament
• #2767
• 2006/11/30 Council Meeting
• 2006/11/30 Act adopted by Council after Parliament's 1st reading
• 2006/06/14 Results of vote in Parliament
  • Results of vote in Parliament
  • T6-0257/2006 summary

    The European Parliament adopted a resolution drafted by Frieda BREPOELS (EPP-ED, BE) and made some amendments to the Commission’s proposal: - It should be one of the Centre's tasks to provide information on best practices and guidelines in the Member States and to facilitate the exchange of such practices among them.- The way in which the Centre is organised and its working methods should be consistent with the objective nature of the results sought, namely the comparability and compatibility of sources and methods in connection with drug information.- Account shall be taken of further WHO and UN data available worldwide.- The Centre should cooperate actively with Europol "to attain maximum efficiency in monitoring the drugs problem".- In principle, the Centre shall, if it identifies new developments and changing trends, inform the competent authorities of the Member States thereof.- The national focal points should draw on the experiences of different sectors - health, justice and law enforcement - in cooperation with experts and national organisations active in the field of drugs policy;- Data on drugs and drug addiction provided to or by the Centre may be published subject to compliance with Community and national rules on the dissemination and confidentiality of information. Personal data may not be published or made accessible to the public. Member States and the national focal points shall be under no obligation to provide information classified as confidential under their national law.-The report put forward a number of amendments to the rules governing the Management Board and Executive Committee as well as the procedure for the appointment of the Director. Moreover, in addition to the requirement for the Director of the Centre to appear at a hearing before Parliament, MEPs also wanted to hold a hearing of the Chairperson of the Management Board. - The Scientific Committee (which assists the Management Board and the Director of the Centre) should not have more than 15 members, who should be selected on the basis of their expertise, by means of an open procedure. MEPs felt that a Scientific Committee consisting of one representative from each Member State would be too unwieldy and would be unable to function independently and efficiently.

• 2006/06/13 Debate in Parliament
  • Debate in Parliament
• 2006/04/03 Committee report tabled for plenary, 1st reading/single reading
  • A6-0124/2006
• 2006/03/23 Vote in committee, 1st reading/single reading
• 2005/09/06 Committee referral announced in Parliament, 1st reading/single reading
• 2005/08/31 Legislative proposal published
  • COM(2005)0399 summary

    PURPOSE: To recast the legislation governing the European Monitoring Centre for Drugs and Drug Addiction.PROPPOSED ACT: Regulation of the European Parliament and of the CouncilCONTENT: Since its inception the European Monitoring Centre for Drugs and Drug Addiction has been amended three times. In addition, recent trends in drug use involving the combination of licit and illicit psychoactive substances requires that the role and scope of the Monitoring Centre needs to be extended and revised yet again. Given the frequent changes to the 1993 Regulation establishing the Centre, combined with the need to make further changes, the Commission proposes, in the interest of clarity, to recast the Regulation.In 2003 the Commission presented a similar recast proposal (COD/2003/0311). Following a consultation process, however, it was decided to re-propose the Regulation under article 152, which requires the co-decision procedure. This present proposal, therefore, cancels and replaces the former Commission proposal.Specifically speaking, the proposed amendments can be summarised as follows:-         Those, which have been designed to boost the Centre’s role, in particular to take account of new drug patterns. Additional amendments are proposed, which improve upon the instruments helping both the Member States and the Commission to monitor and evaluate their respective drugs policies and strategies.-         Those, which have been designed to adapt the operation of the EMCDDA bodies in order to take account of enlargement. The Regulation sets up an Executive Committee to assist the Management Board.-         Those, which have been designed to bring the EMCDDA in line with the Commission’s draft inter-institutional agreement in the framework for European regulatory agencies.-         Those, which codify the three amendments to the basic Regulation already adopted by the Council. -         Those, which have been designed to remove a number of uncertainties arising when the initial Regulation was applied – this refers in particular to the Recitox focal points, instead of the specialised centres.The more technical modifications to the recast Regulation include:-         Extending the list of tasks the EMCDDA is expected to undertake. For example, in future, the EMCDDA will be responsible for collecting and analysing work on emerging trends in poly drug use, such as the combined use of licit and illicit psychoactive substances. It also requires improved synergies in the methodology for data collection and monitoring and it also extends the scope of the Centre’s technical assistance to all countries authorised by the European Council to take part in Community programmes and agencies.-         The Priority Activities of the EMCDDA are adapted in accordance with the new revised tasks outlined above.-         The European Information Network on Drugs and Drug Addiction, Recitox, is amended in order to give it national legal status as well as clarifying their exact functions.-         The legal status of the Centre has been adapted in view of the fact that it has a seat.-         Changes to the Management Board are outlined, including its composition. For example, a new vice chairperson is created and the non voting status of the Management Board members are specified. In addition a new article proposes the creation of an Executive Committee, whose main role is to prepare the decisions of the Management Board.-         A new Article has been introduced relating to fraud. It stipulates that investigations conducted by OLAF will apply the EMCDDA.-         The EMCDDA will be subject, every six years, to external evaluation. On the basis of this evaluation, the Commission may, if appropriate, present proposals amending the EMCDDA Regulation.This proposal has no budgetary implications.

  • DG {'url': 'http://ec.europa.eu/justice/', 'title': 'Justice'}, FRATTINI Franco

Documents

• Legislative proposal published: COM(2005)0399
• Committee report tabled for plenary, 1st reading/single reading: A6-0124/2006
• Debate in Parliament: Debate in Parliament
• Results of vote in Parliament: Results of vote in Parliament
• Decision by Parliament, 1st reading/single reading: T6-0257/2006
• : Regulation 2006/1920
• : OJ L 376 27.12.2006, p. 0001-0013

History

(these mark the time of scraping, not the official date of the change)